Myriad Signs Contract with UnitedHealthcare for MyRisk Hereditary Cancer Risk Panel | GenomeWeb

NEW YORK (GenomeWeb) – Myriad Genetics has signed a three-year contract with national payor UnitedHealthcare to provide access to its next-generation sequencing myRisk Hereditary Cancer test to beneficiaries who meet certain eligibility criteria for hereditary cancer risk.

The myRisk test gauges 25 genes associated with eight hereditary cancers, including breast, colon, ovarian, endometrial, pancreatic, prostate, and gastric cancers, and melanoma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.